| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | NEUTRAL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.19▼ | 2.18▲ | 2.18▲ | 2.20▲ | 2.57▼ |
| MA10 | 2.19▲ | 2.18▲ | 2.18▲ | 2.30▼ | 2.46▼ |
| MA20 | 2.18▲ | 2.18▲ | 2.16▲ | 2.65▼ | 2.22▼ |
| MA50 | 2.19▲ | 2.17▲ | 2.25▼ | 2.43▼ | 2.19▲ |
| MA100 | 2.17▲ | 2.28▼ | 2.46▼ | 2.20▲ | N/A |
| MA200 | 2.19▲ | 2.52▼ | 2.71▼ | 2.01▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | 0.002▲ | 0.010▲ | -0.081▼ | 0.034▲ |
| RSI | 52.131▲ | 53.570▲ | 48.104▼ | 39.934▼ | 49.081▼ |
| STOCH | 73.333 | 50.791 | 43.901 | 13.637▼ | 42.869 |
| WILL %R | -50.000 | -40.000 | -57.143 | -82.472▼ | -78.829▼ |
| CCI | 99.454 | 155.556▲ | 41.105 | -92.709 | -22.402 |
|
Tuesday, November 11, 2025 03:47 PM
Metagenomi (MGX) delivered earnings and revenue surprises of +8.33% and -6.44%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
|
|
Tuesday, November 11, 2025 01:15 PM
New MGX-001 preclinical data supports advancement into clinical development; Demonstrated curative FVIII activity in non-human primates Prioritized later-stage preclinical pipeline including ...
|
|
Tuesday, November 11, 2025 01:15 PM
MGX-001 demonstrated curative FVIII activity in non-human primates Pre-IND regulatory meeting expected in Q4 2025 with investigational new drug ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 11/11/25 | 2.15 | 2.23 | 2.0504 | 2.20 | 297,980 |
| 10/11/25 | 2.19 | 2.275 | 2.15 | 2.15 | 242,798 |
| 07/11/25 | 2.20 | 2.20 | 2.03 | 2.16 | 541,817 |
| 06/11/25 | 2.26 | 2.28 | 2.17 | 2.22 | 189,849 |
| 05/11/25 | 2.335 | 2.34 | 2.2237 | 2.26 | 343,612 |
| 04/11/25 | 2.36 | 2.42 | 2.26 | 2.29 | 353,688 |
| 03/11/25 | 2.51 | 2.55 | 2.34 | 2.42 | 501,629 |
| 31/10/25 | 2.44 | 2.6234 | 2.41 | 2.54 | 257,839 |
| 30/10/25 | 2.35 | 2.48 | 2.322 | 2.44 | 326,430 |
| 29/10/25 | 2.62 | 2.62 | 2.34 | 2.35 | 863,927 |
|
|
||||
|
|
||||
|
|